NASDAQ
Total Transactions
37
10 buys /27 sells
Shares Acquired
83,417
Transactions: 10•Avg: 8,341.7
Shares Disposed
262,710
Transactions: 27•Avg: 9,730
Net Activity
-179,293
Net Selling•Ratio: 37.04%
Q4 2025(Current) | 83,417 | 262,710 | -179,293 | 37.04% |
Q3 2025 | 866,750 | 171,379 | +695,371 | 100.00% |
Q2 2025 | 518,541 | 6,053 | +512,488 | 780.00% |
Q1 2025 | 297,516 | 76,396 | +221,120 | 126.67% |
Q4 2024 | 31,689 | 19,222 | +12,467 | 63.64% |
This table shows insider trading activity by quarter. A ratio > 100% indicates insiders acquired more shares than they disposed of during the period, which is generally considered a bullish signal.
• Most recent data for Q4 2025
Acquired vs Disposed Shares
Net Distribution: 179,293 shares•Acquired/Disposed Ratio: 37.04%
Net Activity | |||||
|---|---|---|---|---|---|
HH Hoppenot Herve | Director | 2 | 0 | 190,343 | -190,343 |
HRA Hoffman Richard A. | Officer: evp & general counsel | 4 | 76,432 | 0 | +76,432 |
GDH Gardner David H | Officer: evp, chief strategy officer | 4 | 75,901 | 0 | +75,901 |
MPA Mayes Patrick A | Officer: evp & chief scientific officer | 20 | 0 | 69,394 | -69,394 |
BRK Basi Ramitpal K | Officer: evp, human resources | 4 | 52,001 | 0 | +52,001 |
This table shows the trading activity of the most active company insiders. Positive net activity (buying more than selling) is often considered a bullish signal.
2025-12-10 | Officer: evp & chief scientific officer | Sale | 5,553 | $95.58 | $530,755.74 | 60,266 | |
2025-12-11 | Officer: evp & chief scientific officer | Sale | 255 | $94.94 | $24,209.7 | 60,011 | |
2025-12-08 | Director | Sale | 2,843 | $96.7 | $274,918.1 | 326,803 | |
2025-12-01 | Officer: evp & chief medical officer | Sale | 2,559 | $102.96 | $263,474.64 | 100,327 | |
2025-12-01 | Officer: evp & chief medical officer | Sale | 17,093 | $102.04 | $1,744,169.72 | 83,234 |
This table displays recent Form 4 filings showing transactions by company insiders. SEC rules require insiders to report their transactions within two business days.
MPA Mayes Patrick A | Officer: evp & chief scientific officer | Dec 12, 2025 | |
MPA Mayes Patrick A | Officer: evp & chief scientific officer | Dec 12, 2025 | |
HH Hoppenot Herve | Director | Dec 10, 2025 | |
SSH Stein Steven H | Officer: evp & chief medical officer | Dec 3, 2025 | |
SSH Stein Steven H | Officer: evp & chief medical officer | Dec 3, 2025 |
Net change in shares shown on right
No price data available for this timeframe.